The Personal Lines segment provides automobile, homeowners and personal umbrella coverage through direct-to-consumer channels and independent agents, while its Property & Casualty Other Operations segment offers coverage for asbestos and environmental exposures.
The Group Benefits segment provides group life, disability and other group coverages to members of employer groups, associations and affinity groups through direct insurance policies; reinsurance to other insurance companies; employer paid and voluntary product coverages; disability underwriting, administration and claims processing to self-funded employer plans; and a single-company leave management solution. This segment distributes its group insurance products and services through brokers, consultants, third-party administrators, trade associations and private exchanges.
The Hartford Funds segment offers investment products for retail and retirement accounts; exchange-traded products through broker-dealer organizations, independent financial advisers, defined contribution plans, financial consultants, bank trust groups and registered investment advisers; and investment management and administrative services, such as product design, implementation and oversight.
Shareholders receive a 2.34% dividend. The BofA Securities target price on Hartford Financial Services stock is $101. The consensus target is lower at $84.71, and shares closed on Monday at $65.77.
Laboratory Corp. of America
Clinical lab testing never goes out of style, and this company is a leader. Laboratory Corp. of America, Holdings (NYSE: LH) operates as an independent clinical laboratory company worldwide. It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures and alcohol and other substance-abuse tests.
The company also provides specialty testing services, comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women’s health, pharmacogenetics and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs and kidney stone prevention tests.
It also provides online and mobile applications to enable patients to check test results, as well as online applications for managed care organizations. It offers end-to-end drug development, medical device and diagnostic development solutions from early-stage research to clinical development and commercial market access.
The company serves managed care organizations, biopharmaceutical companies, physicians and other health care providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions and independent clinical laboratories.
Shareholders receive a 1.19% dividend. The $350 BofA Securities price target is well above the $307.46 consensus target. Laboratory Corporation of America stock closed at $241.31 on Monday.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.